Search

Schizophrenia is a psychiatric disorder that presents with hallucinations, delusions, thought disorders, and cognitive dysfunctions. Antipsychotic monotherapy is effective in the treatment of schizophrenia. In recent years, the main antipsychotics used have been second-generation antipsychotics, also called atypical antipsychotics, which have a slightly lower incidence of side effects. When monotherapy of two or more antipsychotics fails to produce sufficient improvement, a diagnosis of treatment-resistant schizophrenia is made, and clozapine is used.

Purpose: The record block for maxillomandibular registration of the denture is absolutely necessary in order to decide the mandibular position. This record block must provide sufficient strength so as not to cause deformation in the oral cavity. It must also fit the alveolar ridge well in order to keep accurate registration. Since most of the conventional materials for this purpose are not sufficient, a new specific light-polymerized resin was experimentally developed for the record base., Methods: The mechanical strength and suitability of the new material were examined in comparison with a conventional autopolymerizing resin., Results: 1) The transverse strength was equivalent to that of the autopolymerizing resin. 2) Although the shear bond strength was equivalent to the autopolymerizing resin, the intensity was drastically improved by the application of composite primer. 3) The light-polymerized resin and the autopolymerizing resin did not show any difference in suitability, and it was a clinical value without problem., Conclusions: From these findings, it was confirmed that the new light-polymerized resin had the physical property for clinical application as a material for the record base.

We investigated the in vitro and in vivo antibacterial activities of pazufloxacin mesilate (PZFX mesilate), a new injectable quinolone, and obtained the following results. 1) The MIC50 and MIC90 values of PZFX against clinically isolated Gram-positive and -negative bacteria, ranged from 0.0125 to 12.5 micrograms/ml and 0.025 to 100 micrograms/ml, respectively. PZFX showed broad spectrum activity. The antibacterial activities of PZFX against quinolone-susceptible, methicillin-resistant Staphylococcus aureus, beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae, extended spectrum beta-lactamase possessing Klebsiella pneumoniae and imipenem/cilastatine (IPM/CS)-resistant Pseudomonas aeruginosa were superior to those of ceftazidime (CAZ), ceftriaxone, IPM/CS, meropenem and panipenem/betamipron. 2) PZFX showed superior bactericidal activity against S. aureus, Escherichia coli, Proteus mirabilis, Serratia marcescens and P. aeruginosa to those of CAZ and IPM/CS after treatment for 15 minutes at the drug concentration equivalent to that in human serum at clinical dose to be continued for 15 minutes. 3) CAZ and IPM/CS had no bactericidal activity at the 16 times of MIC against P. aeruginosa in human polymorphonuclear leucocytes, while PZFX exhibited potent bactericidal activity in a dose-dependent manner against such bacteria. 4) PZFX inhibited both DNA gyrase and topoisomerase IV from S. aureus at nearly the same level. PZFX showed poor inhibitory activity against topoisomerase II from human placenta and showed high selectivity to bacterial topoisomerase. 5) PZFX mesilate showed superior therapeutic activity to that of CAZ with following infection model caused by S. aureus and P. aeruginosa or each; systemic infection with cyclophosphamide-treated mice, systemic infection in mice with high challenge doses, CMC pouch infection in rat, and calculus infection in rat bladder. 6) Intravenous administration of PZFX with high plasma concentration just after administration, showed more excellent therapeutic effect against the rat intraperitoneal infection, than p.o. and s.c. administration.